文献速递肾小球疾病慢性肾脏病

Alport综合征中足细胞加速脱落与进行性丢失

Accelerated podocyte detachment and progressive podocyte loss from glomeruli with age in Alport Syndrome.
PubMed 文献 · Kidney Int · 2017-07-26

该研究纳入95例基因分型Alport综合征患者(尿液研究)和41份存档活检(活检研究),发现尿足细胞脱落率较对照增加11倍,且早于蛋白尿或微量白蛋白尿出现;肾小球足细胞每年平均丢失26个(对照2.3个),预计约22年进展至终末期肾病。

要点

  • Alport综合征尿足细胞脱落率较对照增加11倍,早于蛋白尿出现。
  • 肾小球足细胞每年丢失26个,对照仅2.3个,差异11倍。
  • 足细胞数量与密度下降与蛋白尿、肾小球硬化及肾功能减退相关。

核心结论

  • Alport综合征足细胞脱落率自出生即增加,驱动疾病进展,可能有助于预测终末期肾病时间及治疗反应。

研究设计与样本

  • 基因分型Alport综合征队列95例用于尿液研究,41份存档活检用于活检研究。

主要发现

  • 尿足细胞脱落率(尿沉渣podocin mRNA/肌酐或24小时排泄)较对照显著增加11倍,且早于可检测的蛋白尿或微量白蛋白尿。
  • Alport综合征肾小球平均每年丢失26个足细胞,对照每年丢失2.3个,差异11倍,与尿足细胞脱落率增加对应。
  • Alport综合征活检肾小球足细胞数预计出生时正常(558个/肾小球),但加速丢失预计约22年导致终末期肾病。
  • 两个独立队列活检数据显示估计肾小球足细胞丢失率相似,与测得的11倍脱落率增加相当。
  • 活检中足细胞数量和密度降低与蛋白尿、肾小球硬化及肾功能减退相关。

临床怎么用

  • 尿podocin mRNA脱落率或可作为Alport综合征早期肾小球损伤标志物,早于蛋白尿出现。
  • 足细胞丢失速率可能用于预测Alport综合征进展至终末期肾病的时间及治疗反应。

局限性

  • 终末期肾病约22年的预测基于足细胞丢失率推算,非直接观察终点。
  • 活检数据来自存档样本,样本量有限(41份)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Podocyte depletion is a common mechanism driving progression in glomerular diseases. Alport Syndrome glomerulopathy, caused by defective α3α4α5 (IV) collagen heterotrimer production by podocytes, is associated with an increased rate of podocyte detachment detectable in urine and reduced glomerular podocyte number suggesting that defective podocyte adherence to the glomerular basement membrane might play a role in driving progression. Here a genetically phenotyped Alport Syndrome cohort of 95 individuals [urine study] and 41 archived biopsies [biopsy study] were used to test this hypothesis. Podocyte detachment rate (measured by podocin mRNA in urine pellets expressed either per creatinine or 24-hour excretion) was significantly increased 11-fold above control, and prior to a detectably increased proteinuria or microalbuminuria. In parallel, Alport Syndrome glomeruli lose an average 26 podocytes per year versus control glomeruli that lose 2.3 podocytes per year, an 11-fold difference corresponding to the increased urine podocyte detachment rate. Podocyte number per glomerulus in Alport Syndrome biopsies is projected to be normal at birth (558/glomerulus) but accelerated podocyte loss was projected to cause end-stage kidney disease by about 22 years. Biopsy data from two independent cohorts showed a similar estimated glomerular podocyte loss rate comparable to the measured 11-fold increase in podocyte detachment rate. Reduction in podocyte number and density in biopsies correlated with proteinuria, glomerulosclerosis, and reduced renal function. Thus, the podocyte detachment rate appears to be increased from birth in Alport Syndrome, drives the progression process, and could potentially help predict time to end-stage kidney disease and response to treatment.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Ding F, Wickman L, Wang SQ, et al. Accelerated podocyte detachment and progressive podocyte loss from glomeruli with age in Alport Syndrome. Kidney Int. 2017. PMID: 28754557. doi:10.1016/j.kint.2017.05.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。